The Centers for Medicare & Medicaid Services (CMS) has proposed two more programmes in the Trump administration's efforts to ...

The FDA has delivered a gift to Novo Nordisk ahead of the holiday season, with the prompt approval of an oral formulation of ...

People in life sciences companies understand how patents are crucial to their business, by setting competitive boundaries, ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Tarek Samad, Lundbeck’s senior vice president and head ...

But the digital-first promise carried a blind spot: it solves for tasks, not emotions. Patients don’t start, stay on, or ...

It's notable that Ipsen has bolted on more than 20 early-stage programmes since 2020 as part of a push to become a major ...

"Our goal in the LATIFY trial was to reinvigorate the immune response of patients with lung cancer whose tumours stopped ...

AstraZeneca will voluntarily take its anticoagulant reversal agent Andexxa off the market in the US in light of FDA concerns ...

Vossman discusses the genomics landscape, as well as next-generation sequencing (or NGS), and the Model Project, a ...

Combined, the two drugs made revenues of nearly $600 million in the last four quarters, while BioMarin has forecast that its ...

Yet, many medical affairs teams remain bound to traditional workflows. Linear processes and siloed functions are struggling ...

US companies Amgen, Bristol Myers Squibb, Gilead Sciences, and Merck/MSD have signed up to reduce the prices of medicines for ...